Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Novo Nordisk

Status

Enrolling

Conditions

Haemophilia A

Congenital Bleeding Disorder

Treatments

Drug: Turoctocog alfa

Study type

Observational

Funder types

Industry

Identifiers

NCT06574984

NN7008-7871

Details and patient eligibility

About

The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.

Enrollment

900 estimated patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion criteria

Paediatric and adult male patients
On-demand and prophylactic patients with haemophilia A (any severity)
Only previously treated patients (previous FVIII replacement therapy) will be included in the study

Exclusion criteria

Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
Patients with documented presence of any FVIII inhibitor